Lisata Therapeutics Inc (LSTA)

[Viperciara]

Caladrius Biosciences’ (CLBS) Buy Rating Reiterated at Maxim Group

December 28th, 2015 - By Maddie Sorensen - 0 comments

Caladrius Biosciences logoCaladrius Biosciences (NASDAQ:CLBS)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research report issued on Monday, AnalystRatings.Net reports.

CLBS has been the subject of a number of other research reports. Zacks Investment Research upgraded Caladrius Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. WBB Securities restated a “buy” rating and issued a $7.00 price target on shares of Caladrius Biosciences in a research note on Thursday, September 24th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Caladrius Biosciences currently has a consensus rating of “Buy” and a consensus price target of $9.67.

Shares of Caladrius Biosciences (NASDAQ:CLBS) traded down 2.59% during midday trading on Monday, reaching $1.13. The company’s stock had a trading volume of 218,040 shares. The firm’s market cap is $62.57 million. The stock’s 50 day moving average price is $1.16 and its 200 day moving average price is $1.53. Caladrius Biosciences has a one year low of $1.01 and a one year high of $4.26.

Caladrius Biosciences, Inc., formerly NeoStem, Inc., is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (NASDAQ:CLBS). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy), which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10, which has completed Phase I clinical trials. Under T Regulatory Cell Program, the Company is developing NBS03D, which is in the Phase I clinical trial stage
http://www.dakotafinancialnews.com/caladrius-biosciences-clbs-buy-rating-reiterated-at-maxim-group/767227/